China Sows Ground For TCM Market Growth With Regulatory Framework
This article was originally published in The Tan Sheet
A long-awaited law could greatly enlarge the traditional Chinese medicine market and has prompted drug makers in the country to race to develop TCM products. The potential TCM boom has multinational drug firms leaping into the fray, some to partner with locals and others establishing teams devoted to TCM R&D.
You may also be interested in...
Bayer acquired its second Chinese consumer health care firm to gain market share amid the country’s OTC consolidation trend. Dihon specializes in antifungal creams and herbal drugs for women’s and traditional Chinese medicines.
A regulatory framework that encourages physicians to conduct experimental cell and gene therapies have propelled China to become a major developer of such promising cancer-treating tools, but insiders say three are a plethora issues at stake.
Prices of direct acting hepatitis C drugs are down by 85% in China, with cancer and antidiabetes therapy costs cut by 65% and drug makers are rushing to celebrate. Scrip delves into the considerations behind the low prices and whether industry's excitement is a bit premature.